Influence of dexmedetomidine on hemodynamic parameters in critical ill patients

Influence of dexmedetomidine on hemodynamic parameters in critical ill patients with delirium: a single center prospective study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN13101129

Enrollment

Registered

2017-08-22

Start date

2016-02-01

Completion date

Unknown

Last updated

2017-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critically ill patients with occurring delirium after admission to ICU Mental and Behavioural Disorders Delirium, unspecified

Interventions

Twelve consecutive ICU patients with agitated delirium according to Richmond Agitation Sedation Scale (RASS) were assigned to receive dexmedetomidine (DEX). Dexmedetomidine is part of the normal routi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Critically ill patients (18 years and older) with occurring delirium after admission to ICU. For delirium screening the Confusion Assessment Method (CAM-ICU) and Richmond Agitation-Sedation-Scale (RASS) were used.

Exclusion criteria

Exclusion criteria: 1. Younger than 18 years 2. Pregnancy 3. Known drug intolerance or allergy against dexmedetomidine 4. Increased intracranial pressure 5. Patients with cerebrale pathology, which changes the controllability of sedation or die consciousness 6. Myasthenia Gravis 7. Cerebellar or spinal Ataxia 8. Enzyme related disorders that are associated with a severe decreased activity of UDP-glucoronyltransferase (e.g. M. Crigler- Najjar) 9. Chronic liver insufficiency CHILD A, B or C

Design outcomes

Primary

Measure	Time frame
Cardiac power index is measured using the transpulmonary thermodilution technique (PiCCO) at the individual maximum dosage of dexmedetomidine (0.3µg/kg/h or 0.7µg/kg/h) and compared to baseline values (dexmedetomidine, 0 µg/kg/h)	—

Secondary

Measure	Time frame
1. Cardiac index (CI) is measured using the transpulmonary thermodilution technique (PiCCO) 2. Systemic vascular resistance index (SVRI) is measured using the transpulmonary thermodilution technique (PiCCO) 3. Global end diastolic volume index (GEDVI) is measured using the transpulmonary thermodilution technique (PiCCO) 4. Extravascular lung water index (EVLWI) is measured using the transpulmonary thermodilution technique (PiCCO) 5. Pulmonary vascular permeability index (PVPI) is measured using the transpulmonary thermodilution technique (PiCCO) 6. Heart rate (HR) is measured permanently via 5-French thermistor tipped arterial catheter 7. Mean arterial pressure (MAP) is measured permanently via 5-French thermistor tipped arterial catheter Transpulmonary thermodilution measurements were performed at following timepoints and concentrations: 0h: dexmedetomidine: 0 µg/kg/h 2h: dexmedetomidine: 0.3µg/kg/h 4h: dexmedetomidine: 0.7µg/kg/h 2h after therapy with dexmedetomidine was stopped or as soon as predefined termination criteria (HR <60/min and/or MAP<65mmHg) were fulfilled	—

Measure

Time frame

1. Cardiac index (CI) is measured using the transpulmonary thermodilution technique (PiCCO) 2. Systemic vascular resistance index (SVRI) is measured using the transpulmonary thermodilution technique (PiCCO) 3. Global end diastolic volume index (GEDVI) is measured using the transpulmonary thermodilution technique (PiCCO) 4. Extravascular lung water index (EVLWI) is measured using the transpulmonary thermodilution technique (PiCCO) 5. Pulmonary vascular permeability index (PVPI) is measured using the transpulmonary thermodilution technique (PiCCO) 6. Heart rate (HR) is measured permanently via 5-French thermistor tipped arterial catheter 7. Mean arterial pressure (MAP) is measured permanently via 5-French thermistor tipped arterial catheter Transpulmonary thermodilution measurements were performed at following timepoints and concentrations: 0h: dexmedetomidine: 0 µg/kg/h 2h: dexmedetomidine: 0.3µg/kg/h 4h: dexmedetomidine: 0.7µg/kg/h 2h after therapy with dexmedetomidine was stopped or as soon as predefined termination criteria (HR <60/min and/or MAP<65mmHg) were fulfilled

—

Countries

Germany

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026